Literature DB >> 12714563

Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth.

Shingo Ameshima1, Heiko Golpon, Carlyne D Cool, Daniel Chan, R William Vandivier, Shyra J Gardai, Marilee Wick, Raphael A Nemenoff, Mark W Geraci, Norbert F Voelkel.   

Abstract

PPARgamma is a member of a family of nuclear receptors/ligand-dependent transcription factors, which bind to hormone response elements on target gene promoters. An antiproliferative and proapoptotic action profile of PPARgamma has been described and PPARgamma may function as a tumor suppressor gene, but little is known about the role of PPARgamma in vascular remodeling. One group of human diseases that shows impressive vascular remodeling exclusively in the lungs is the group of severe pulmonary hypertensive disorders, which is characterized by complex, endothelial cell-proliferative lesions of lung precapillary arterioles composed of clusters of phenotypically altered endothelial cells that occlude the vessel lumen and contribute to the elevation of the pulmonary arterial pressure and reduce local lung tissue blood flow. In the present study, we report the ubiquitous PPARgamma expression in normal lungs, and in contrast, a reduced lung tissue PPARgamma gene and protein expression in the lungs from patients with severe PH and loss of PPARgamma expression in their complex vascular lesions. We show that fluid shear stress reduces PPARgamma expression in ECV304 endothelial cells, that ECV304 cells that stably express dominant-negative PPARgamma (DN-PPARgamma ECV304) form sprouts when placed in matrigel and that DN-PPARgamma ECV304 cells, after tail vein injection in nude mice, form lumen-obliterating lung vascular lesions. We conclude that fluid shear stress decreases the expression of PPARgamma in endothelial cells and that loss of PPARgamma expression characterizes an abnormal, proliferating, apoptosis-resistant endothelial cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714563     DOI: 10.1161/01.RES.0000073585.50092.14

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  118 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry.

Authors:  Yingfeng Wang; Wenju Lu; Kai Yang; Yan Wang; Jie Zhang; Jing Jia; Xin Yun; Lichun Tian; Yuqin Chen; Qian Jiang; Bo Zhang; Xiuqing Chen; Jian Wang
Journal:  J Mol Med (Berl)       Date:  2014-11-14       Impact factor: 4.599

Review 3.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

Review 4.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

5.  Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury.

Authors:  Ke-Jie Yin; Zhen Deng; Milton Hamblin; Yi Xiang; Huarong Huang; Jifeng Zhang; Xiaodan Jiang; Yanzhuang Wang; Y Eugene Chen
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 6.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

7.  Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.

Authors:  Meiqian Weng; Michael J Raher; Patricio Leyton; Terry P Combs; Philipp E Scherer; Kenneth D Bloch; Benjamin D Medoff
Journal:  Am J Respir Cell Mol Biol       Date:  2010-11-12       Impact factor: 6.914

8.  Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells.

Authors:  Justine I Blum; Kaiser M Bijli; Tamara C Murphy; Jennifer M Kleinhenz; C Michael Hart
Journal:  Am J Med Sci       Date:  2016-04-04       Impact factor: 2.378

9.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

10.  Chronic inhibition of PPAR-γ signaling induces endothelial dysfunction in the juvenile lamb.

Authors:  Shruti Sharma; Jubilee Barton; Ruslan Rafikov; Saurabh Aggarwal; Hsuan-Chang Kuo; Peter E Oishi; Sanjeev A Datar; Jeffrey R Fineman; Stephen M Black
Journal:  Pulm Pharmacol Ther       Date:  2012-12-17       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.